UK markets open in 7 hours 45 minutes

Poxel S.A. (0RA2.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
1.60000.0000 (0.00%)
At close: 08:29AM BST
Full screen
Previous close1.6000
Open5.6442
Bid0.0000 x 0
Ask0.0000 x 0
Day's range1.6000 - 1.6000
52-week range0.2985 - 1.6000
Volume78,599
Avg. volume3,158
Market cap39.496M
Beta (5Y monthly)1.55
PE ratio (TTM)N/A
EPS (TTM)-0.8300
Earnings date21 Jun 2024 - 22 Jun 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update

    LYON, France, May 16, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today reported its revenue for the quarter ended March 31, 2024 and provided a business update.

  • Business Wire

    Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release

    LYON, France, April 29, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today reported its cash position, provided a financial and business update for the first quarter ended March 31, 2024, and announced the postponement of its 2023 full-year results re

  • Business Wire

    Poxel to Report Its 2023 Annual Results by the End of April 2024

    LYON, France, March 28, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announces the publication at the end of April 2024 of its 2023 Annual Results, originally scheduled for April 9, 2024, given the expected completion of a transaction by the end of April.